Evolent Health (EVH)
(Delayed Data from NYSE)
$24.57 USD
-0.20 (-0.81%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $16.13 -8.44 (-34.35%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$24.57 USD
-0.20 (-0.81%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $16.13 -8.44 (-34.35%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Zacks News
Evolent Health (EVH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 66.67% and 2.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
EngageSmart (ESMT) Matches Q4 Earnings Estimates
by Zacks Equity Research
EngageSmart (ESMT) delivered earnings and revenue surprises of 0% and 3.08%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Down 29.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolent Health (EVH)
by Zacks Equity Research
Evolent Health (EVH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Evolent Health (EVH) Q3 Earnings Top Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 637.50% and 0.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Evolent Health (EVH) Outperforming Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Here is how Evolent Health (EVH) and KVH Industries (KVHI) have performed compared to their sector so far this year.
Is Absolute Software (ABST) Stock Outpacing Its Computer and Technology Peers This Year?
by Zacks Equity Research
Here is how Absolute Software Corporation (ABST) and Evolent Health (EVH) have performed compared to their sector so far this year.
What Makes Evolent Health (EVH) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Evolent Health (EVH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Predict a 28% Upside in Evolent Health (EVH): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 28.3% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Evolent Health (EVH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 233.33% and 9.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: New Relic (NEWR) Q1 Earnings Expected to Decline
by Zacks Equity Research
New Relic (NEWR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolent Health (EVH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Evolent Health (EVH) a Good Fit for "Trend Investing"
by Zacks Equity Research
Evolent Health (EVH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here's Why Evolent Health (EVH) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Evolent Health (EVH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Has Evolent Health (EVH) Outpaced Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Here is how Evolent Health (EVH) and KT Corp. (KT) have performed compared to their sector so far this year.
Has eGain (EGAN) Outpaced Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Here is how eGain (EGAN) and Evolent Health (EVH) have performed compared to their sector so far this year.
Evolent Health (EVH) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Evolent Health (EVH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts Believe Evolent Health (EVH) Could Rally 38%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Evolent Health (EVH) points to a 37.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Has Airgain (AIRG) Outpaced Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Here is how Airgain (AIRG) and Evolent Health (EVH) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for May 25th
by Zacks Equity Research
CIB, IOSP, and EVH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 25, 2022.
Can Evolent Health (EVH) Climb 39% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 38.6% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zendesk (ZEN) Misses Q4 Earnings Estimates
by Zacks Equity Research
Zendesk (ZEN) delivered earnings and revenue surprises of -11.11% and 1.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Digital Turbine (APPS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Digital Turbine (APPS) delivered earnings and revenue surprises of 13.95% and 6.34%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Paylocity (PCTY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Paylocity (PCTY) delivered earnings and revenue surprises of 56.10% and 4.35%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Evolent Health (EVH) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Evolent Health (EVH) delivered earnings and revenue surprises of 0.00% and -1.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Evolent Health (EVH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.